<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03763773</url>
  </required_header>
  <id_info>
    <org_study_id>2017_30</org_study_id>
    <secondary_id>2018-A01463-52</secondary_id>
    <nct_id>NCT03763773</nct_id>
  </id_info>
  <brief_title>Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome</brief_title>
  <acronym>PreMiTE-ARDS</acronym>
  <official_title>Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Superior Vena cava Respiratory Collapse Index (cVCS) is a haemodynamic parameter measured
      exclusively by transoesophageal ultrasound (TEE), which is used to assess cardiac
      precharge-dependence status. This may be an important prognostic factor in ARDS because it is
      a sign of hypervolemia and right heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days lived without mechanical ventilation</measure>
    <time_frame>at 28 days</time_frame>
    <description>This variable will be defined as follows:duration = 28 -x -y. where x is the number of days living under mechanical ventilation during the first 28 days and the number of days in the first 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patient of death</measure>
    <time_frame>At 28 days, at 90 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with mechanical ventilation hospitalized in intensive care, emergency or intensive
        care units
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized in Resuscitation, Emergency or Intensive Care Units at the Roger
             Salengro Hospital at Lille University Hospital.

          -  With acute respiratory distress syndrome of intermediate or severe severity (1) for
             less than 24 hours.

          -  Mechanical ventilation with tracheal intubation or tracheostomy, in controlled
             assisted ventilation (VAC) mode.

          -  Patient adapted to mechanical ventilation (no triggering of spontaneous ventilation
             cycle in VAC mode verified by the equality between the respiratory rate prescribed on
             the ventilator and the actual respiratory rate of the patient).

        Exclusion Criteria:

          -  Patient under extracorporeal respiratory assistance at the time of inclusion.

          -  Anomalies or pathologies that make it dangerous or impossible to introduce an ETO
             probe:

               -  Fistula, perforation, stenosis, varicose vein or diverticulum of the esophagus
                  and / or stomach

               -  History of esophageal and / or gastric surgery

               -  Caustic lesions of the esophagus and / stomach

               -  Tumor or history of oropharyngeal surgery

               -  Unstable lesions of the cervical spine

               -  Coagulopathy (thrombocytopenia &lt;50 109 / L and / or TP &lt;50%).

          -  Impossibility of measuring the diameter of the superior vena cava and cVCS in ETO due
             to poor echogenicity.

          -  Pregnant woman.

          -  Therapeutic limitation measures limiting the treatment of organ failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Preau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien Preau, MD</last_name>
    <phone>03.20.44.44.95</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.preau@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sébastien Preau, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>respiratory variations,</keyword>
  <keyword>superior vena cava</keyword>
  <keyword>prognosis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

